Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Research on adverse drug reactions detailed by J. Roigas and co-authors
November 25th, 2008
"Targeted agents, including the multitargeted receptor tyrosine kinase inhibitor sunitinib, have demonstrated clinical efficacy in the first- and second-line treatment of patients with metastatic renal cell carcinoma (mRCC). These agents have dramatically improved the outlook for such patients," investigators in Berlin, Germany report. "However, treatment with targeted agents is associated with a distinct pattern of adverse events (AE) that must be effectively managed for patients to derive maximum possible benefit. To review the AEs observed in sunitinib studies as well as practical therapy-management strategies to maximize clinical benefit with targeted agents in...
Source: Cancer Weekly (2008-11-25)
|
